Ocean Biomedical Inc
NASDAQ:OCEA
Ocean Biomedical Inc
Ocean Biomedical, Inc. is a biopharmaceutical company. The company is headquartered in Providence, Rhode Island. The company went IPO on 2021-09-15. The firm is focused on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The firm helps to accelerates the development and commercialization of assets from research universities and medical centers. In oncology, it is engaged in developing a mono-specific and two bi-specific humanized monoclonal antibodies (mAb), product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer (NSCLC), and of glioblastoma multiforme (GBM). The company offers three product candidates based on the novel target discoveries: a malaria vaccine candidate targeting either or both of PfSEA-1, and parasite antigen PfGARP, which is referred to as its ODA-570 candidate; a humanized mAb malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-611 candidate, and a small molecule malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-579 candidate.
Ocean Biomedical, Inc. is a biopharmaceutical company. The company is headquartered in Providence, Rhode Island. The company went IPO on 2021-09-15. The firm is focused on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The firm helps to accelerates the development and commercialization of assets from research universities and medical centers. In oncology, it is engaged in developing a mono-specific and two bi-specific humanized monoclonal antibodies (mAb), product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer (NSCLC), and of glioblastoma multiforme (GBM). The company offers three product candidates based on the novel target discoveries: a malaria vaccine candidate targeting either or both of PfSEA-1, and parasite antigen PfGARP, which is referred to as its ODA-570 candidate; a humanized mAb malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-611 candidate, and a small molecule malaria therapeutic candidate targeting PfGARP, which is referred to as ODA-579 candidate.
